A Real-World, Multicenter, 6-Month Prospective Study in Greece of the Effectiveness and Safety of Ranibizumab in Patients with Age-Related Macular Degeneration Who Have Inadequately Responded to Aflibercept: The "ELEVATE" Study.
Alexandros RouvasIoannis DatserisSofia AndroudiMiltiadis TsilimbarisStamatina A KabanarouNikolaos PharmakakisChryssanthi KoutsandreaAlexander CharonisOlga C KousidouGeorgia N PantelopoulouPublished in: Clinical ophthalmology (Auckland, N.Z.) (2022)
Six-month treatment with ranibizumab in aflibercept inadequate responders led to visual acuity and PED GBD improvements, with no statistically significant CRT change.